Therapeutic equivalents in clinical practice

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Pharmacology

Background:

• Rising healthcare expenses necessitate cost-saving strategies.
• Previous measures like gatekeeping and reduced hospital stays faced challenges with patient satisfaction and safety.
• Generic drugs, or therapeutic equivalents, represent an underappreciated cost-saving success.

Purpose of the Study:

• To highlight the economic impact and effectiveness of generic drug prescription.
• To examine the role of legislation in promoting the generic drug market.
• To assess the contribution of generic drugs to healthcare cost containment.

Main Methods:

• Analysis of the Hatch-Waxman Act of 1984 and its impact on generic drug approval.
• Examination of market share and expenditure data for branded versus generic drugs.
• Review of regulatory requirements for generic drug approval, including bioavailability and shelf life.

Main Results:

• The generic drug industry's market share grew from under 20% in 1984 to approximately 44% in recent years.
• Despite increased market share, generic drugs account for only 8% of total prescription medication expenditures.
• The Hatch-Waxman Act facilitated generic drug market entry by streamlining FDA approval.

Conclusions:

• Prescription of therapeutic equivalents is a proven method for reducing healthcare costs.
• Generic drugs provide significant cost savings without compromising patient satisfaction or safety.
• Legislation like the Hatch-Waxman Act has been pivotal in expanding access to affordable generic medications.